# US 2013/0330314 A1 · Metal Abstraction Peptide With Superoxide Dismutase Activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0330314 A1
- Document ID: US20130330314A1
- Status: Published application
- Kind: A1
- Application number: 13/905,457
- Filed: 2013-05-30
- Published: 2013-12-12
- Earliest claimed: 2012-06-01
- Assignees: Echogen, Inc.; University of Kansas
- Applicants: Echogen, Inc.; University of Kansas
- Inventors: Jennifer Ann Stowell Laurence; Mary Elizabeth Krause; Timothy A. Jackson; Amanda Michelle Glass; George Laurence
- Web page: https://patentgrep.com/patent/US20130330314A1

## CPC

- C12N 9/0089: {acting on superoxide as acceptor (1.15)}
- C07K 14/62: Insulins
- C12P 7/62: Carboxylic acid esters
- C12Y 115/01001: Superoxide dismutase (1.15.1.1)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12Y: ENZYMES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Compositions comprising peptides that are capable of binding a metal are disclosed. Such compositions can be used for binding metal in a variety of contexts and environments. In various embodiments, peptides are used for antioxidant activity, anti-inflammatory activity, anti-pain therapy, as chemical reagents, and/or as superoxide dismutase mimics.

## Claims

### Claim 1

A method of treating a defect in superoxide dismutase in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of:
i) a peptide comprising a sequence XC1C2, wherein X is any natural or non-natural amino acid or amino acid analog, and further wherein C1 and C2 are each individually chosen from a cysteine and a sulfur-containing alpha or beta amino acid; and
ii) a metal bound to the peptide.

### Claim 2 (depends on 1)

The method of claim 1, wherein the peptide and the metal are in a unit dosage form, wherein the unit dosage form further comprises a pharmaceutically-acceptable excipient.

### Claim 3 (depends on 1)

The method of claim 1, wherein the sequence XC1C2 is of all L-amino acids.

### Claim 4 (depends on 1)

The method of claim 1, wherein the sequence XC1C2 is of an achiral amino acid and two L-amino acids.

### Claim 5 (depends on 1)

The method of claim 1, wherein the sequence XC1C2 is of an achiral amino acid and two D-amino acids.

### Claim 6 (depends on 1)

The method of claim 1, wherein the sequence XC1C2 is included in a sequence Z1-XC1C2, wherein Z1 is any natural or non-natural amino acid or sequence of natural or non-natural amino acids.

### Claim 7 (depends on 1)

The method of claim 1, wherein the sequence XC1C2 is included in a sequence XC1C2-Z2, wherein Z2 is any natural or non-natural amino acid or sequence of natural or non-natural amino acids.

### Claim 8 (depends on 1)

The method of claim 1, wherein the sequence XC1C2 is included in a sequence Z1-XC1C2-Z2, wherein Z1 and Z2 are each individually any natural or non-natural amino acid or sequence of natural or non-natural amino acids.

### Claim 9 (depends on 1)

The method of claim 1, wherein the peptide comprises a basic amino acid adjacent to either X or C2.

### Claim 10 (depends on 1)

The method of claim 1, wherein C1 and C2 are each cysteine.

### Claim 11 (depends on 1)

The method of claim 1, wherein X is asparagine.

### Claim 12 (depends on 1)

The method of claim 1, wherein the metal is a group 10 metal.

### Claim 13 (depends on 1)

The method of claim 1, wherein the metal is nickel.

### Claim 14 (depends on 1)

The method of claim 1, wherein the composition has a concentration of the peptide and a concentration of the metal, and further wherein the concentration of the peptide and the concentration of the metal are in a ratio from about 1:about 2 to about 2:about 1.

### Claim 15 (depends on 14)

The method of claim 14, wherein the ratio is about 1:about 1.

### Claim 16 (depends on 1)

The method of claim 1, wherein the sequence XC1C2 binds the metal.

### Claim 17 (depends on 1)

The method of claim 1, wherein the peptide binds the metal in a square planar orientation.

### Claim 18 (depends on 1)

The method of claim 1, wherein the peptide binds the metal in a square pyramidal orientation.

### Claim 19 (depends on 1)

The method of claim 1, wherein the peptide comprises at least 20 amino acids.

### Claim 20 (depends on 19)

The method of claim 19, wherein the peptide comprises no more than 500 amino acids.

### Claim 21 (depends on 1)

The method of claim 1, wherein the amount is from about 1 to about 50 mg.

### Claim 22 (depends on 1)

The method of claim 1, wherein a complex of the peptide and the metal acts as a preservative.

### Claim 23 (depends on 1)

The method of claim 1, wherein a complex of the peptide and the metal acts as an antioxidant.

### Claim 24 (depends on 1)

The method of claim 1, wherein the amount is from about 0.001% to about 0.1% w/v.

### Claim 25 (depends on 1)

The method of claim 1, wherein the administration is intravenous.

### Claim 26

A method of reducing pain in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of:
i) a peptide comprising a sequence XC1C2, wherein X is any natural or non-natural amino acid or amino acid analog, and further wherein C1 and C2 are each individually chosen from a cysteine and a sulfur-containing alpha or beta amino acid; and
ii) a metal bound to the peptide.

### Claim 27 (depends on 26)

The method of claim 26, wherein the peptide and the metal are in a unit dosage form, wherein the unit dosage form further comprises a pharmaceutically-acceptable excipient.

### Claim 28 (depends on 26)

The method of claim 26, wherein the sequence XC1C2 is of all L-amino acids.

### Claim 29 (depends on 26)

The method of claim 26, wherein the sequence XC1C2 is of an achiral amino acid and two L-amino acids.

### Claim 30 (depends on 26)

The method of claim 26, wherein the sequence XC1C2 is of an achiral amino acid and two D-amino acids.

### Claim 31 (depends on 26)

The method of claim 26, wherein the sequence XC1C2 is included in a sequence Z1-XC1C2, wherein Z1 is any natural or non-natural amino acid or sequence of natural or non-natural amino acids.

### Claim 32 (depends on 26)

The method of claim 26, wherein the sequence XC1C2 is included in a sequence XC1C2-Z2, wherein Z2 is any natural or non-natural amino acid or sequence of natural or non-natural amino acids.

### Claim 33 (depends on 26)

The method of claim 26, wherein the sequence XC1C2 is included in a sequence Z1-XC1C2-Z2, wherein Z1 and Z2 are each individually any natural or non-natural amino acid or sequence of natural or non-natural amino acids.

### Claim 34 (depends on 26)

The method of claim 26, wherein the peptide comprises a basic amino acid adjacent to either X or C2.

### Claim 35 (depends on 26)

The method of claim 26, wherein C1 and C2 are each cysteine.

### Claim 36 (depends on 26)

The method of claim 26, wherein X is asparagine.

### Claim 37 (depends on 26)

The method of claim 26, wherein the metal is a group 10 metal.

### Claim 38 (depends on 26)

The method of claim 26, wherein the metal is nickel.

### Claim 39 (depends on 26)

The method of claim 26, wherein the composition has a concentration of the peptide and a concentration of the metal, and further wherein the concentration of the peptide and the concentration of the metal are in a ratio from about 1:about 2 to about 2:about 1.

### Claim 40 (depends on 39)

The method of claim 39, wherein the ratio is about 1:about 1.

### Claim 41 (depends on 26)

The method of claim 26, wherein the sequence XC1C2 binds the metal.

### Claim 42 (depends on 26)

The method of claim 26, wherein the peptide binds the metal in a square planar orientation.

### Claim 43 (depends on 26)

The method of claim 26, wherein the peptide binds the metal in a square pyramidal orientation.

### Claim 44 (depends on 26)

The method of claim 26, wherein the peptide comprises at least 20 amino acids.

### Claim 45 (depends on 44)

The method of claim 44, wherein the peptide comprises no more than 500 amino acids.

### Claim 46 (depends on 26)

The method of claim 26, wherein the amount is from about 1 to about 5000 mg.

### Claim 47 (depends on 26)

The method of claim 26, wherein a complex of the peptide and the metal acts as a preservative.

### Claim 48 (depends on 26)

The method of claim 26, wherein a complex of the peptide and the metal acts as an antioxidant.

### Claim 49 (depends on 26)

The method of claim 26, wherein the amount is from about 0.001% to about 0.1% w/v.

### Claim 50 (depends on 26)

The method of claim 26, wherein the administration is intravenous.

### Claim 51

A method of reducing inflammation in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of:
i) a peptide comprising a sequence XC1C2, wherein X is any natural or non-natural amino acid or amino acid analog, and further wherein C1 and C2 are each individually chosen from a cysteine and a sulfur-containing alpha or beta amino acid; and
ii) a metal bound to the peptide.

### Claim 52 (depends on 51)

The method of claim 51, wherein the peptide and the metal are in a unit dosage form, wherein the unit dosage form further comprises a pharmaceutically-acceptable excipient.

### Claim 53 (depends on 51)

The method of claim 51, wherein the sequence XC1C2 is of all L-amino acids.

### Claim 54 (depends on 51)

The method of claim 51, wherein the sequence XC1C2 is of an achiral amino acid and two L-amino acids.

### Claim 55 (depends on 51)

The method of claim 51, wherein the sequence XC1C2 is of an achiral amino acid and two D-amino acids.

### Claim 56 (depends on 51)

The method of claim 51, wherein the sequence XC1C2 is included in a sequence Z1-XC1C2, wherein Z1 is any natural or non-natural amino acid or sequence of natural or non-natural amino acids.

### Claim 57 (depends on 51)

The method of claim 51, wherein the sequence XC1C2 is included in a sequence XC1C2-Z2, wherein Z2 is any natural or non-natural amino acid or sequence of natural or non-natural amino acids.

### Claim 58 (depends on 51)

The method of claim 51, wherein the sequence XC1C2 is included in a sequence Z1-XC1C2-Z2, wherein Z1 and Z2 are each individually any natural or non-natural amino acid or sequence of natural or non-natural amino acids.

### Claim 59 (depends on 51)

The method of claim 51, wherein the peptide comprises a basic amino acid adjacent to either X or C2.

### Claim 60 (depends on 51)

The method of claim 51, wherein C1 and C2 are each cysteine.

### Claim 61 (depends on 51)

The method of claim 51, wherein X is asparagine.

### Claim 62 (depends on 51)

The method of claim 51, wherein the metal is a group 10 metal.

### Claim 63 (depends on 51)

The method of claim 51, wherein the metal is nickel.

### Claim 64 (depends on 51)

The method of claim 51, wherein the composition has a concentration of the peptide and a concentration of the metal, and further wherein the concentration of the peptide and the concentration of the metal are in a ratio from about 1:about 2 to about 2:about 1.

### Claim 65 (depends on 64)

The method of claim 64, wherein the ratio is about 1:about 1.

### Claim 66 (depends on 51)

The method of claim 51, wherein the sequence XC1C2 binds the metal.

### Claim 67 (depends on 51)

The method of claim 51, wherein the peptide binds the metal in a square planar orientation.

### Claim 68 (depends on 51)

The method of claim 51, wherein the peptide binds the metal in a square pyramidal orientation.

### Claim 69 (depends on 51)

The method of claim 51, wherein the peptide comprises at least 20 amino acids.

### Claim 70 (depends on 69)

The method of claim 69, wherein the peptide comprises no more than 500 amino acids.

### Claim 71 (depends on 69)

The method of claim 69, wherein the amount is from about 1 to about 5000 mg.

### Claim 72 (depends on 51)

The method of claim 51, wherein a complex of the peptide and the metal acts as a preservative.

### Claim 73 (depends on 51)

The method of claim 51, wherein a complex of the peptide and the metal acts as an antioxidant.

### Claim 74 (depends on 51)

The method of claim 51, wherein the amount is from about 0.001% to about 0.1% w/v.

### Claim 75 (depends on 51)

The method of claim 51, wherein the administration is intravenous.

### Claim 76

A method of increasing in vivo half-life of a therapeutic polypeptide, the method comprising:
i) providing a therapeutic polypeptide with an amino terminus, wherein the amino terminus has a sequence XC1C2, wherein X is any natural or non-natural amino acid or amino acid analog, and further wherein C1 and C2 are each individually chosen from a cysteine and a sulfur-containing alpha or beta amino acid;
ii) forming a complex between a metal and the therapeutic polypeptide under conditions suitable for chiral inversion of C2; and
iii) separating the metal from the therapeutic polypeptide with chirally inverted C2, wherein the in vivo half-life of the therapeutic polypeptide is increased.

### Claim 77 (depends on 76)

The method of claim 76, wherein X is a chiral amino acid, and further wherein X is chirally inverted.

### Claim 78 (depends on 76)

The method of claim 76, wherein C2 has L-stereochemistry prior to chiral inversion.

### Claim 79 (depends on 76)

The method of claim 76, wherein C1 and C2 are each cysteine.

### Claim 80 (depends on 76)

The method of claim 76, wherein the metal is a group 10 metal.

### Claim 81 (depends on 76)

The method of claim 76, wherein the metal is nickel.

### Claim 82 (depends on 76)

The method of claim 76, wherein the sequence XC1C2 binds the metal.

### Claim 83 (depends on 76)

The method of claim 76, wherein the therapeutic polypeptide binds the metal in a square planar orientation.

### Claim 84 (depends on 76)

The method of claim 76, wherein the therapeutic polypeptide binds the metal in a square pyramidal orientation.

### Claim 85 (depends on 76)

The method of claim 76, wherein the therapeutic polypeptide comprises at least 20 amino acids.

### Claim 86 (depends on 85)

The method of claim 85, wherein the therapeutic polypeptide comprises no more than 500 amino acids.

### Claim 87 (depends on 85)

The method of claim 85, wherein the therapeutic polypeptide adopts a tertiary structure under physiological conditions, wherein a basic amino acid located at least 17 amino acids away from C1 by amino acid sequence is located within 20 angstroms in space from C1.

### Claim 88 (depends on 76)

The method of claim 76, wherein the therapeutic polypeptide is insulin.

### Claim 89 (depends on 76)

The method of claim 76, wherein the conditions suitable for chiral inversion comprise exposure to an electron transfer agent.

### Claim 90 (depends on 89)

The method of claim 89, wherein the electron transfer agent is molecular oxygen.

### Claim 91

A method of performing a chemical reaction, the method comprising contacting:
i) a peptide comprising a sequence XC1C2, wherein X is any natural or non-natural amino acid or amino acid analog, wherein C1 and C2 are each individually chosen from a cysteine and a sulfur-containing alpha or beta amino acid, and wherein a metal is bound to the peptide; and
ii) chemical starting materials,
whereupon the chemical starting materials are combined into a product.

### Claim 92 (depends on 91)

The method of claim 91, wherein the peptide is XC1C2.

### Claim 93 (depends on 91)

The method of claim 91, wherein C1 and C2 are each cysteine.

### Claim 94 (depends on 91)

The method of claim 91, wherein X is asparagine.

### Claim 95 (depends on 91)

The method of claim 91, wherein the metal is a group 10 metal.

### Claim 96 (depends on 91)

The method of claim 91, wherein the metal is nickel.

### Claim 97 (depends on 91)

The method of claim 91, wherein the sequence XC1C2 binds the metal.

### Claim 98 (depends on 91)

The method of claim 91, wherein the peptide binds the metal in a square planar orientation.

### Claim 99 (depends on 91)

The method of claim 91, wherein the peptide binds the metal in a square pyramidal orientation.

### Claim 100 (depends on 91)

The method of claim 91, wherein the product comprises at least two chemical starting materials linked by at least one covalent bond.

### Claim 101 (depends on 91)

The method of claim 91, wherein the chemical reaction is a polymerization reaction.

### Claim 102 (depends on 91)

The method of claim 91, wherein a complex of the peptide and the metal acts as an initiator.

### Claim 103 (depends on 91)

The method of claim 91, wherein a complex of the peptide and the metal acts as a radical scavenger.

### Claim 104 (depends on 91)

The method of claim 91, wherein the peptide has from 3 to about 10 amino acids.
